A Long-Term Extension Study of RoActemra/Actemra (Tocilizumab) in Patients With Juvenile Idiopathic Arthritis From France Who Completed WA19977 Core Study

Exclusion Criteria

• •Patients with, according to investigator judgment, not satisfactory benefit from RoActemra/Actemra therapy within WA19977
• •Treatment with any investigational agent since the last administration of study drug in the core study WA19977
• •Patient developed any other autoimmune rheumatic disease or overlap syndrome other than the permitted polyarticular-course Juvenile Idiopathic Arthritis (JIA) subsets: rheumatoid factor positive or negative JIA or extended oligoarticular JIA
• •Patient is pregnant , lactating, or intending to become pregnant during the study and up to 12 weeks after the last administration of study drug
• •Any significant concomitant disease or medical or surgical condition
• •History of significant allergic or infusion reactions to prior biologic therapy
• •Currently active primary or secondary immunodeficiency
• •Any infections with contraindications to RoActemra/Actemra therapy according to investigator judgment
• •Inadequate hepatic, renal or bone marrow function